AIM2 and prostate cancer: In consistence with our study, AIM2 was demonstrated to inhibit proliferation and tumorigenicity in breast cancer, renal carcinoma, and prostate cancer (Chen et al., 2006; Ponomareva et al., 2013; Chai et al., 2018).